Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies

Key Points

• The study aims to evaluate the clinical benefit of zanidatamab for treating HER2-positive salivary gland cancer (SGC).
• Combined analysis of early-phase studies
• Evaluation of treatment outcomes in HER2-positive SGC patients
• Assessment of clinical benefit despite small sample size
• Findings indicate clinical benefit from zanidatamab treatment
• Results suggest effectiveness for patients with unresectable or metastatic HER2-positive SGC

Abstract